🏥 Health
1d ago
Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year
Source ↗
👁 2
💬 0
(MedPage Today) -- Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP), according...
Comments (0)